For the Inventor, By the Inventor

Enter assignee name

Emeryville, CA, United States of America

Eureka Therapeutics, Inc.

USPTO Granted Patents = 48

EPO Patents = 10

Trademarks = 4

Forward Citations = 172

Loading Chart...

Loading Chart...

42 inventors (with patents filed for the assignee):

Cheng Liu (38 out of 46 patents)

Hong Liu (20 out of 21 patents)

Su Yan (19 out of 19 patents)

4. Renier J Brentjens (16 out of 19 patents)

5. Yiyang Xu (15 out of 15 patents)

6. Eric L Smith (15 out of 85 patents)

7. Jingyi Xiang (10 out of 11 patents)

8. Zhiyuan Yang (9 out of 12 patents)

9. Lucas Horan (9 out of 9 patents)

10. Tao Dao (8 out of 11 patents)

11. David A Scheinberg (8 out of 49 patents)

12. Jingwei Lu (7 out of 7 patents)

13. Vivien Wai-Fan Chan (6 out of 6 patents)

14. Pengbo Zhang (5 out of 5 patents)

15. Lianxing Liu (5 out of 5 patents)

Core Competencies:

Chimeric Antigen Receptors

Mucin-16

Prostate-Specific Membrane Antigen

B-Cell Maturation Antigen

G-Protein Coupled Receptor

T Cell Receptor-Like Antibodies

Monoclonal Antibodies

Fc Receptor-Like 5

48 patents: Sort by Forward Citations

1. 12168696 - Antibodies to mucin-16 (MUC16), encoding polynucleotides and methods of treating MUC16-positive cancer (2024-12-17),

2. 12139538 - Chimeric antigen receptors targeting Fc receptor-like 5 and uses thereof (2024-11-12),

3. 11993661 - Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof (2024-05-28),

4. 11981742 - Antibody agents specific for human CD19 and uses thereof (2024-05-14),

5. 11976105 - Antibody/T-cell receptor chimeric constructs and uses thereof (2024-05-07),

6. 11965021 - Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof (2024-04-23),

7. 11866478 - Nucleic acid molecules encoding chimeric antigen receptors targeting G-protein coupled receptor (2024-01-09),

8. 11827672 - Constructs trageting CD22 and uses thereof (2023-11-28),

9. 11820806 - Chimeric antigen receptors targeting G-protein coupled receptor and uses thereof (2023-11-21),

10. 11725059 - Antibodies targeting B-cell maturation antigen and methods of use (2023-08-15),

11. 11673957 - Anti-ROR2 antibodies (2023-06-13),

12. 11613573 - Chimeric antibody/T-cell receptor constructs and uses thereof (2023-03-28),

13. 11566071 - Nucleic acid molecules encoding anti-GPRC5D antibodies (2023-01-31),

14. 11505599 - T cell receptor-like antibodies specific for Foxp3-derived peptides (2022-11-22),

15. 11447564 - Constructs specifically recognizing glypican 3 and uses thereof (2022-09-20),

Eureka Therapeutics, Inc. is a biotechnology company focused on the discovery and development of novel T-cell therapies for the treatment of cancer. They utilize their proprietary E-ALPHA™ discovery platform to identify and engineer T-cell therapies that are designed to target and eliminate cancer cells. Eureka Therapeutics is dedicated to advancing innovative and effective therapies to improve the lives of patients battling cancer.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

48 Patents

#13 in Emeryville, CA

#1,667 in California

#7,025 in US

#14,122 in the World

Emeryville, CA, United States of America

Eureka Therapeutics, Inc.

Forward Citations = 172

42 inventors:

Cheng Liu (38 out of 46 patents)

Hong Liu (20 out of 21 patents)

Su Yan (19 out of 19 patents)

4. Renier J Brentjens (16 out of 19 patents)

5. Yiyang Xu (15 out of 15 patents)

Please report any incorrect information to support@idiyas.com

Loading…